Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet — Clinical Trial Site

79 Registered trials

21 Currently recruiting

Organisation

Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet

Location

Szolnok, Hungary

Identifier

ORG-100041273

Address

Toszegi Ut 21, 5000, Hungary

Departments

348005: Mozgasszervi Centrum Ortopediai Osztalya
7812: Kardiológiai Osztály
Cardiology Department
County Oncology Center
Department of Oncology
Endocrinology
Endocrinology and Internal Medicine
III Belgyógyászati Osztály
Kardiologia
Kardiologiai Osztaly
Megyei Onkológiai Központ
Megyei Onkológiai Centrum
Megyei Onkológiai Centrum (Department of Oncology)
Megyei Onkológiai Központ
N/A
NA
Oncology
Onkológiai Központ
Onkologiai Osztaly
Pulmonológia
Pulmonologiai Osztaly
Tüdőgyógyászati osztály
Vármegyei Onkológia Központ
Varmegyei Onkologiai Kozpont

Clinical trials at this site (79)

Search interface

A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised

2022-500030-28-00 Urothelial carcinoma 4
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Non-small Cell Lung Cancer (NSCLC) 9 2026-04-15
A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting

2024-518839-11-00 Stage IV Squamous Non-Small Cell Lung Cancer 4 2025-08-25
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting

2025-520478-20-00 Thromboembolic disease 5 2025-11-05
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation. Recruiting

2025-521377-14-00 Atrial fibrillation 4 2025-10-06
A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting

2024-518761-10-00 Non-small Cell Lung Cancer 4 2025-08-25
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di… Recruiting

2023-509234-19-00 Participants With Newly Diagnosed Resectable Stages II- 4 2025-03-03
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting

2023-507778-42-00 Non-Small Cell Lung Cancer II, III 4 2023-03-08
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12